Cost-effectiveness analysis of emicizumab use in hospitalized older individuals with acquired hemophilia A Authors: Ming Y Lim, Satoko Ito, George Goshua, Nathorn Chaiyakunapruk, Minkyoung Yoo, Richard Nelson Published: 2026 ABSTRACT Key Points•Although effective for AHA management, emicizumab remains underused in hospitals due to its high cost.•Addition of up-front emicizumab to rFVIIa vs rFVIIa alone yielded lower total direct cost and improved health states. Introduction Acquired hemophilia A (AHA) is a rare, autoimmune disease that occurs due to the development of autoantibodies (inhibitors) against coagulation factor VIII (FVIII), leading to a severe bleeding diathesis with a high morbidity and mortality.1,2 AHA disproportionately affects the older population, with approximately half of reported cases found to be associated with autoimmune diseases, malignancies, and medications.3 The 2 major goals of management in AHA are to achieve hemostatic control and to eradicate the FVIII inhibitor using immunosuppressive therapies (IST).1,4 The bypassing agents, recombinant activated FVII (rFVIIa) and activated prothrombin complex concentrate (aPCC), as well as recombinant porcine FVIII (rpFVIII) can be used for hemostatic control in AHA. Both rFVIIa and rpFVIII were approved by the US Food and Drug Administration for the treatment of AHA in 1996 and 2014, respectively, whereas aPCC is commonly used in an off-label manner. However, these therapies carry disadvantages, including frequent IV infusions and increased thromboembolic risk with the use of bypassing agents, and the development of anti-porcine antibodies with rpFVIII.1,5,6 In addition, until the FVIII inhibitor is eradicated using IST, these individuals remain at high risk of recurrent bleeding requiring recurrent frequent hospitalizations for hemostatic control. Emicizumab is a recombinant, bispecific, monoclonal antibody that bridges FIXa and FX leading to activation of FX and subsequently thrombin generation, thus promoting hemostasis.7,8 Because of its structure, emicizumab can circumvent the need for FVIII and is not affected by FVIII inhibitors.9,10 Although emicizumab is approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in individuals with congenital hemophilia A with or without FVIII inhibitors, it is currently not approved for use in individuals with AHA in the United States. It is currently approved in Japan to prevent or reduce the frequency of bleeding episodes in individuals with AHA.11 The efficacy and safety of off-label emicizumab use in the inpatient management of AHA have been reported in case reports, case series, and 2 prospective multicenter open-label clinical trials.12, 13, 14, 15, 16, 17, 18 In the United States, the AHAEmi study, a phase 2 prospective, multicenter, open-label study to evaluate the efficacy of emicizumab with concurrent IST in individuals with AHA is ongoing (ClinicalTrials.gov identifier: NCT05345197) with results due in mid-2026. However, because of the high cost of emicizumab, hospital administrators are hesitant to include it on the hospital formulary, and its cost-effectiveness remains uncertain. We sought to fill this gap by evaluating the cost-effectiveness of up-front emicizumab use with a standard hemostatic agent, rFVIIa, vs rFVIIa alone (standard of care [SOC]) in older individuals newly diagnosed with AHA who were hospitalized for bleeding control. Methods Model population The AHA cohort was constructed based on patient profiles derived from real-world evidence, which included retrospective cohort studies.12, 13, 14,19 We performed an extensive literature search to identify clinical trials and observational cohort studies involving older adults with AHA who were hospitalized for bleeding to provide estimates for the model parameters (Table 1). Table 1.Input parameters usedParameterBase-case estimateProbability distribution (range/95% CI)Study or data sourceMedian age at diagnosis, y76Fixed18Mean body weight, kg81.9Fixed20Dose of emicizumab on day 16 mg/kgGamma15,18Dose of emicizumab on day 23 mg/kgGamma15,18Dose of rFVIIa90 μg/kgFixed21No. of infusions of rFVIIa per day3FixedExpert opinionMedian duration of rFVIIa therapy with emicizumab and SOC, d1Beta (range, 1-10)13Median duration of rFVIIa therapy with SOC, d7.5Beta (range, 3-33)13Median length of hospitalization with emicizumab and SOC, d5.5Gamma (range, 0-25)13Median length of hospitalization with SOC, d20Gamma (range, 1-44)13Transition probabilitiesBase-case estimateProbability distribution (range)Study or data source Without emicizumab Stop bleeding with rFVIIa0.912Beta (95% CI, 0.857-0.951)19 New bleeding0.50 at 20 d0.034 per dBeta (95% CI, 0.399-0.600 at 20 d)Beta (95% CI, 0.025-0.045)22 Mortality0.00065Beta (range, 0-0.25)12,19 With emicizumab Stop bleeding with rFVIIa0.912Beta (95% CI, 0.857-0.951)19 New bleeding8/47 = 0.1702 over 20 d0.009 per dBeta (95% CI, 0.0765-0.3081)Beta (95% CI, 0.004-0.018)18 Mortality0Beta (range, 0-0.0065)12,13,15,18,19CostBase-case estimate (US$)Probability distribution (range)Study or data source rFVIIa (NovoSeven) 1 μg2.407Fixed23 Emicizumab 1 mg102.444Gamma23 Hospital day3288Gamma (range, 1064-4819)24UtilitiesBase-case estimateProbability distribution (range)Study or data source Bleeding0.66Beta (SD range, 0.4-0.9)25 No bleeding0.82Beta (SD range, 0.6-1.0)25 Hospitalization−0.0003Fixed26 Death00Expert opinionCI, confidence interval; SD, standard deviation. Input parameters used CI, confidence interval; SD, standard deviation. Model structure We built a Markov cohort model to evaluate the cost-effectiveness of up-front emicizumab use compared with no emicizumab use in older adults newly diagnosed with AHA who were admitted for bleeding during their first hospitalization. In this model, there were 5 different health states: (1) bleeding, (2) stop bleeding/observation, (3) new bleeding, (4) discharge, and (5) death (Figure 1). States 4 and 5 were absorbing states, from which no additional transitions could occur. We assumed that each transition cycle was 1 day (24 hours). All older adults with AHA in the model were admitted to the hospital with bleeding, and thus, all entered the model at state 1. In each subsequent cycle, older adults with AHA either continue to have bleeding (ie, remain in state 1), stop bleeding (ie, transition to state 2), or die (ie, transition to state 5). If older adults with AHA stop bleeding (ie, in state 2), they can be discharged from hospital (ie, transition to state 4) or develop a new bleed (that is, transition to state 3). If older adults with AHA develop a new bleed (ie, in state 3), they either continue to have bleeding (ie, remain in state 3), stop bleeding (ie, transition to state 2), or die (ie, transition to state 5). We assumed that there were no thrombotic events with the use of rFVIIa although this has been reported in the literature (albeit rarely).27 Markov model for older adults with AHA hospitalized for bleeding. Health states include the bleeding states (bleeding and new bleeding), nonbleeding states (stop bleeding/observation and discharge), and death. All individuals enter the model in the bleeding state. A time horizon of 20 days was used for the cost-effectiveness analysis (CEA) based on the median length of hospitalization in an observational cohort of individuals with AHA.13 The CEA was conducted from the health system perspective within the United States,28 and we did not discount future outcomes because the time horizon was <1 year. Model outcomes The outcomes of the model were hospital cost (from medication use and hospital stay) and the cumulative total utilities for each health state within each arm. The latter was measured using quality-adjusted life days (QALDs), which are the product of the utility value of the state at 20 days. These outcomes were used to calculate the incremental cost-effectiveness ratio as the difference in total costs divided by the difference in effectiveness between the 2 arms, reformulated also as the incremental net monetary benefit (iNMB) across all accepted willingness-to-pay thresholds in the United States, anchored at a threshold of $120 000 per quality-adjusted life years gained (equivalent to a threshold of $329 per QALD).29,30 Clinical parameters Clinical parameter estimates were derived from the best available medical literature based on clinical trials and observational studies conducted on individuals with AHA (Table 1). Depending on the parameter, data from either a subgroup or all participants in the studies were used. Expert judgment with consultation with a hematologist with expertise in management of AHA was used if no suitable source was available. To determine the days an individual with AHA continued bleeding (ie, remain in state 1) while hospitalized, our model used duration in days of rFVIIa therapy in each arm that were informed by a case series of 21 older adults with newly diagnosed AHA.13 The hemostatic efficacy of rFVIIa, defined as the probability of bleeding cessation, was informed by data from the European Acquired Haemophilia (EACH2) registry, a prospective observational study of consecutive European patients with AHA.19 Because emicizumab requires a 2-day loading regimen (day 1, 6 mg/kg; day 2, 3 mg/kg) to reach therapeutic levels, the same hemostatic efficacy for rFVIIa was applied to both arms during the hospitalization. We also assumed that the hemostatic efficacy of rFVIIa remained constant across initial and subsequent new bleeding events. The probability of dying from bleeding during the hospitalization with up-front emicizumab use was informed by multiple clinical studies and real-world data, which found no deaths occurred in the first 20 days.12,13,15,18 In contrast, estimating the probability of dying due to bleeding during hospitalization with rFVIIa monotherapy was challenging, given the substantial variability reported across different studies. A real-world evidence study of 12 Japanese individuals with AHA reported a 25% death rate during hospitalization,12 whereas the EACH2 registry found that 10 of 307 individuals with AHA treated with a hemostatic therapy died as a result of bleeding (mortality, 3.3%).19 Of these 10 individuals with AHA who died, 2 did so within the first day of hospitalization, whereas the remaining 8 died on days 15, 16, 23, 23, 25, 27, 163, and 184, respectively. Given that the median length of stay in the rFVIIa arm was 20 days, we estimated the probability of dying from bleeding during hospitalization as 4 of 307, which was then converted to a daily probability of dying. We opted to use this assumption rather than the 25% reported in the Japanese study12 to conservatively favor the null hypothesis (ie, that up-front emicizumab is not cost-effective). The probability of new bleeding while on emicizumab was informed by the prospective GTH-AHA-EMI study that provided data on the number of new bleeding events in the first 3 weeks (21 days) since the first dose of emicizumab (of 47 enrolled individuals, 8 individuals experienced bleeding while on emicizumab).18 This was converted to a daily probability of new bleeding while on emicizumab. The probability of new bleeding while on rFVIIa monotherapy was informed by the prospective GTH-AH 01/2010 study, which provided data showing that ∼50% of 102 individuals had at least 1 bleeding event by day 20; this was again converted to a daily probability of new bleeding while on rFVIIa monotherapy.22 When in the bleeding state, a regimen of rFVIIa at 90 μg/kg every 2 hours for a total of 3 doses was infused per day. When a new bleeding occurred, the same regimen of rFVIIa at 90 μg/kg every 2 hours for a total of 3 doses was infused per day. For this model, there was no switching from rFVIIa to a different hemostatic agent (aPCC or rpFVIII). All clinical parameters, except for emicizumab dosing, the rFVIIa regimen, and length of hospital stay, were subjected to sensitivity analyses given the variability and heterogeneity of older adults with AHA and their reported health states in the literature. Length of hospital stay was directly linked to the duration of rFVIIa treatment. Specifically, once an older adult with AHA stopped bleeding (transition to stage 2) and discontinued rFVIIa, they could be discharged in the next transition cycle (transition to stage 4). Given the strong correlation between length of hospital stay and duration of rFVIIa treatment, and the fact that duration of rFVIIa treatment was already varied in sensitivity analyses, we did not conduct a separate sensitivity analysis for length of hospital stay. Cost parameters Only direct institutional costs in US dollars were used in the model. Older adults with AHA admitted for bleeding were assumed to start rFVIIa at a dose of 90 μg/kg, 3 times per day, when in the bleeding health state. Older adults with AHA in the up-front emicizumab cohort were assumed to start subcutaneous emicizumab on day 1, 6 mg/kg and day 2, 3 mg/kg to reach therapeutic levels. Subsequent weekly maintenance dose of 1.5 mg/kg from day 8 was not included because it was expected that those on the emicizumab arm would have been discharged by day 8 based on the median length of hospitalization in an observational cohort of individuals with AHA who received up-front emicizumab.13 Medication prices were sourced from Medicare average sales pricing (rFVIIa, HCPCS J7189; emicizumab, HCPCS J7170)23 and age-specific body weights were sourced from the US Centers for Disease Control and Prevention.20 The cost variable for hospital stay was subjected to sensitivity analyses.24 Utility parameters Utilities were scaled from 0 to 1, with 0 representing death and 1 representing perfect health. For our analyses, the utility estimates for health states 1 (ie, continuous bleeding) and 2 (ie, stop bleeding) were informed by the mean health state for bleeding vs nonbleeding days of a cohort of individuals with congenital hemophilia and inhibitors.25 The median age of this latter cohort was 17.2 years (range, 2.1-60.9). Given the median age of older adults with AHA used for this study (76 years),18 the utility estimates used are likely an overestimation, however, the disutility of bleeding should still be comparable. Because the up-front emicizumab arm is expected to be discharged from hospital sooner than the SOC arm, we also added the disutility of ongoing hospitalization per day to the bleeding and new bleeding states.26 Sensitivity analyses We quantified the uncertainty within the parameters of our model with a series of deterministic analyses and probabilistic sensitivity analyses (PSA). In a series of 1-way deterministic sensitivity analyses, we varied all parameters across their known 95% confidence intervals or used the range reported from clinical studies. If neither was known, we varied by ±10% of the absolute point estimate. We also performed a PSA in which we varied all model parameters to assess the robustness of the model. For the PSA, we performed 10 000 Monte Carlo simulations, each randomly sampling from the entire distribution of model inputs, with clinical probabilities and health utilities represented by beta distributions and costs represented by gamma distributions. The model was constructed using TreeAge Pro Healthcare 2024 (TreeAge Software, Williamstown, MA), and our report was in adherence with the Consolidated Health Economic Evaluation Reporting Standards guideline. Results In this Markov model, over a 20-day hospitalization time horizon, the addition of up-front emicizumab to SOC was associated with lower total costs ($248 934) compared with SOC alone ($569 038) and an improvement in QALDs (15.92 for up-front emicizumab vs 14.72 for SOC), resulting in an incremental cost savings of $320 104, a gain of 1.2 QALDs, and an iNMB of $320 105 (Table 2). In other words, the addition of up-front emicizumab was dominant compared with SOC alone (Figure 2). Table 2.Baseline CEA for total costs, effectiveness, ICER, and NMB, as appropriateStrategyCost (US$)Incremental costs (US$)Effectiveness (QALD)Incremental effectiveness (QALD)ICER ($/QALD)NMB ($)SOC569 038—14.72−568 643SOC and emicizumab248 933−320 10415.921.20Dominant−248 538ICER, incremental cost-effectiveness ratio. Baseline CEA for total costs, effectiveness, ICER, and NMB, as appropriate ICER, incremental cost-effectiveness ratio. Base-case incremental cost-effectiveness plot and scatterplot of the PSA of up-front emicizumab use with rFVIIa compared with rFVIIa alone. Base-case incremental cost-effectiveness for up-front emicizumab use with rFVIIa is represented by the orange circle. The scatterplot of the PSA for up-front emicizumab use with rFVIIa is represented by the green circles. The ellipse represents the 95% confidence ellipse of outcomes for the PSA. Incr., incremental; WTP, willingness-to-pay. We performed 1-way sensitivity analyses on the following parameters: duration of rFVIIa treatment; cost of hospital stay per day; probability of stop bleeding, new bleeding, and dying on each arm; and the utility values for the bleeding and nonbleeding states. Among these parameters, the duration of rFVIIa use on both arms had the greatest impact on the iNMB (Figure 3). Increasing the days of rFVIIa use in the emicizumab arm to >7 days reduced the iNMB to $0, indicating that emicizumab is no longer cost-effective (Figure 3). In contrast, reducing the days of rFVIIa use in the rFVIIa monotherapy arm improves its NMB, but even when reduced to 3 days of rFVIIa use, the emicizumab arm still dominated. The probability of dying on the SOC arm also significantly influenced the iNMB (−$31 032 to $322 162). The probability of new bleeding and stop bleeding in both arms had no impact on the NMB, whereas the cost of hospital stay per day had a minimal impact. Tornado diagram comparing the iNMB of emicizumab plus rFVIIa vs rFVIIa alone, with the WTP threshold set at US$329 per QALD. Each horizontal bar represents the impact of uncertainty in a specific parameter on the NMB. The baseline iNMB is US$320 499, as the length of the bar indicates the range of NMB values resulting from the variation of that parameter within its plausible limits. EV, estimated value; prob, probability; WTP, willingness-to-pay. The robustness of the model to all input variables was further confirmed by the PSA using 10 000 iterations in a Monte Carlo simulation. The incremental cost-effectiveness plane scatterplot showed that up-front emicizumab use with rFVIIa was in the southeast (lower right) quadrant, indicating a more effective and less costly strategy (Figure 2). The cost-effectiveness acceptability curve showed that the addition of up-front emicizumab use to rFVIIa was favored over rFVIIa alone in 100% of 10 000 iterations in a Monte Carlo simulation, regardless of willingness-to-pay threshold (supplemental Figure 1). Discussion In this study, using data obtained from previously published retrospective studies and registry sources, we demonstrated that the addition of emicizumab (despite its high list price) to SOC treatment with rFVIIa in the acute management of hospitalized individuals with AHA resulted in a lower overall cost with higher quality of care. This indicated that the addition of emicizumab is dominant. We observed this finding despite having incorporated factors designed to favor SOC. The ranges for mortality rate in individuals with AHA on SOC alone varied widely. In our model, we chose the lowest mortality rate to maximize the benefit of the SOC arm. Additionally, we capped the rFVIIa dosing regimen at a maximum of 3 doses per day for both arms. This likely underestimates true use because current recommendations suggest dosing every 2 to 3 hours until hemostasis is achieved,21 and individuals experiencing active bleeding typically require many more doses of rFVIIa per day. This increased dosing frequency would further elevate costs in the SOC arm, particularly because these individuals had a longer duration of daily rFVIIa use. Considering all these factors, this reinforces that up-front use of emicizumab is an even more dominant strategy than our models conservatively estimate. Our finding is unsurprising, because both clinical trials and real-world studies have consistently shown that emicizumab decreases use of costly hemostatic agents, shortens hospital length of stay, and reduces infection- and bleed-related mortality.12,13,15,18,31,32 Yet, despite robust evidence of clinical value, its high list price has persisted as a major obstacle to hospital formulary inclusion, primarily owing to its substantial up-front budget implications. Our results therefore support that up-front emicizumab use improves clinical outcome while simultaneously reducing overall hospital expenditure. This study adds to the literature in being, to our knowledge, the first to examine the cost-effectiveness of up-front emicizumab use with rFVIIa as a hemostatic agent. Two previous CEAs, conducted before the availability of emicizumab, only compared the 3 different hemostatic agents, rFVIIa, aPCC, and rpFVIII, over a time horizon of 6 days, and found that aPCC dominated the other 2 agents.33,34 aPCC achieved similar QALDs (4.91 vs 4.90 vs 4.89) but incurred a much lower cost ($1778 vs $13 925 vs $6957) compared with rFVIIa and rpFVIII, respectively.34 However, given the black box warning of thrombotic microangiopathy and thrombotic events observed when emicizumab is used concurrently with aPCC,35 we opted to compare using rFVIIa as the SOC. It is possible that using aPCC (instead of rFVIIa) in the SOC arm could have yielded more favorable results for SOC, and will be an area of future study. Our finding has several important implications. Currently, emicizumab use in AHA management is concentrated in academic medical centers and less common in community hospitals, largely due to concerns about its high cost. Our results provide strong economic and clinical justification for pharmacy and therapeutics committees to consider up-front emicizumab use and include it in hospital formularies, regardless of practice setting. Such adoption promotes equitable access to care by reducing the need for transfers to tertiary centers, enabling older adults with AHA to receive high-quality treatment closer to home. By incorporating emicizumab into local formularies, community hospitals can deliver advanced therapies without compromising outcomes. Additional studies using longer term follow-up data are warranted to assess the full impact of emicizumab in the outpatient management of older adults with AHA. This study has a few limitations. First, we used retrospective observational studies that have small sample sizes. However, given the rarity of this disease, larger sample sizes may not be easily obtainable. Although one could use AHA registry data such as the EACH2 registry,19 registry data typically report the overall management of AHA including both inpatient and outpatient management, whereas this study is focused on the inpatient management of AHA. Second, our study focused on older adults, and the findings may not be generalizable to younger populations. We anticipate that younger adults presenting with newly diagnosed AHA and requiring hospitalization for bleeding management may have lower mortality compared with older cohorts. However, in constructing our model for older adults, we deliberately selected the lowest mortality rates reported in the literature to conservatively maximize the benefit of the SOC arm. As such, the model’s conclusions are likely broadly applicable to younger adults, although this extrapolation should be interpreted with caution. Prospective data in younger AHA populations would be valuable to validate these assumptions. Third, because utility values for the bleeding and nonbleeding state for individuals with AHA do not exist, we used values obtained from individuals with congenital hemophilia with FVIII inhibitors. However, this cohort was much younger than those with AHA. Although the utility in older adults is expected to be much lower, we anticipate the disutility of bleeding to be similar regardless of age. Fourth, we excluded thrombotic outcomes in our model because this is a rare, albeit important, outcome with the use of rFVIIa. Fifth, we only looked at the use of rFVIIa as the SOC hemostatic option, instead of comparing with the other 2 hemostatic options available, aPCC and rpFVIII. As discussed earlier, we did not compare with aPCC given the black box warning. As for rpFVIII, it is used far less frequently in clinical practice.36 Data from the Medicare Limited Data Set indicate that only 18% of hospitalizations for AHA received rpFVIII, compared with substantially higher use of rFVIIa.36 Given this pattern of use, rFVIIa was considered the more generalizable comparator for contemporary clinical practice. In conclusion, we performed a CEA on up-front emicizumab use in older adults with AHA hospitalized for bleeding and found that adding emicizumab to SOC treatment with rFVIIa was dominant, even at current emicizumab drug pricing. Future work should focus on quantifying the long-term outpatient impact of initiating up-front emicizumab in AHA management, incorporating the potential observed benefits of reducing rehospitalization and delaying IST initiation on both overall and infection-related mortality.32 We strongly recommend that hospital pharmacy and therapeutics committees incorporate emicizumab into their formularies because this represents a cost-effective strategy that offers immediate benefits in hemostatic control. Conflict-of-interest disclosure: M.Y.L. reports honoraria for participation in advisory boards for Sanofi, Hema Biologics, and SeraGene Therapeutics. The remaining authors declare no competing financial interests.